10x Genomics Q2 Earnings Exceed Expectations, Stock Surges
ByAinvest
Friday, Aug 8, 2025 8:19 am ET1min read
TEM--
However, the company missed its revenue guidance for the next quarter, with the guidance of $142 million falling 1.5% short of analyst expectations of $145.4 million [2]. Despite this, 10x Genomics has shown consistent performance, surpassing consensus EPS estimates three times over the last four quarters [1].
The company's stock has shown resilience despite underperforming the S&P 500 this year, losing about 11.8% since the beginning of the year compared to the S&P 500's gain of 7.9% [1].
Investors should keep an eye on the company's earnings outlook and management's commentary on the earnings call to gauge the stock's immediate price movement. The Zacks Rank, which incorporates earnings estimate revisions, currently rates 10x Genomics as a #2 (Buy) [1].
The outlook for the Medical Info Systems industry, in which 10x Genomics operates, is favorable, with the industry ranking in the top 37% of the 250 plus Zacks industries [1].
Tempus AI (TEM), another healthcare technology company in the same industry, is expected to report its results on August 8. The company is anticipated to post a quarterly loss of $0.23 per share, representing a year-over-year change of +63.5% [1].
Investors should consider the broader industry trends and the company's specific performance when evaluating 10x Genomics as an investment opportunity.
References:
[1] https://www.nasdaq.com/articles/10x-genomics-txg-surpasses-q2-earnings-and-revenue-estimates
[2] https://finance.yahoo.com/news/earnings-watch-10x-genomics-txg-030947742.html
TXG--
10x Genomics reported Q2 CY2025 revenue of $172.9 million, up 12.9% YoY and beating analyst estimates by 24%. However, next quarter's revenue guidance of $142 million fell 1.5% short of analyst expectations. The company's GAAP profit of $0.28 per share was significantly above consensus estimates.
10x Genomics (TXG) reported quarterly earnings and revenue for the period ending June 2025, marking a significant improvement over the previous year. The company's adjusted earnings per share (EPS) of $0.28 surpassed the Zacks Consensus Estimate of a loss of $0.35 per share, representing an earnings surprise of +180.00% [1]. This quarterly report also saw the company's revenue reach $172.91 million, up 12.9% year-over-year (YoY) and beating analyst estimates by 24.00% [1].However, the company missed its revenue guidance for the next quarter, with the guidance of $142 million falling 1.5% short of analyst expectations of $145.4 million [2]. Despite this, 10x Genomics has shown consistent performance, surpassing consensus EPS estimates three times over the last four quarters [1].
The company's stock has shown resilience despite underperforming the S&P 500 this year, losing about 11.8% since the beginning of the year compared to the S&P 500's gain of 7.9% [1].
Investors should keep an eye on the company's earnings outlook and management's commentary on the earnings call to gauge the stock's immediate price movement. The Zacks Rank, which incorporates earnings estimate revisions, currently rates 10x Genomics as a #2 (Buy) [1].
The outlook for the Medical Info Systems industry, in which 10x Genomics operates, is favorable, with the industry ranking in the top 37% of the 250 plus Zacks industries [1].
Tempus AI (TEM), another healthcare technology company in the same industry, is expected to report its results on August 8. The company is anticipated to post a quarterly loss of $0.23 per share, representing a year-over-year change of +63.5% [1].
Investors should consider the broader industry trends and the company's specific performance when evaluating 10x Genomics as an investment opportunity.
References:
[1] https://www.nasdaq.com/articles/10x-genomics-txg-surpasses-q2-earnings-and-revenue-estimates
[2] https://finance.yahoo.com/news/earnings-watch-10x-genomics-txg-030947742.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet